Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 4Waldenstrom Macroglobulinemia 3Multiple Myeloma 3Burkitt Lymphoma 3Lymphoma, Follicular 2Plasmablastic Lymphoma 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Effusion 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Intraocular Lymphoma 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 9Cyclophosphamide 8fludarabine 5dacetuzumab 5blinatumomab 5Brentuximab Vedotin 4Bendamustine Hydrochloride 4ibrutinib 3fludarabine phosphate 3Vincristine 3Prednisone 3Melphalan 3Etoposide 3Doxorubicin 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Ifosfamide 2Everolimus 2Carboplatin 2Busulfan 2Bone Marrow Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × pomalidomide × Lymphoid × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡